INCR1 and neoplasm: While IL12 treatment activated the PBMC cytotoxic effects against both control and INCR1 knockdown tumor cells, we found a significant increase in the cytotoxicity of PBMCs on INCR1 knockdown tumor cells compared to control (Fig. 3B-C).